HONG KONG – Japan's Carna Biosciences Inc. and Sumitomo Dainippon Pharma Co. Ltd. signed an agreement potentially worth about $100 million to work together on the research, development and commercialization of novel kinase inhibitors, focusing on psychiatric and neurological disorders.
HONG KONG – Looking to improve regulatory coordination and supervision of drug and food markets, the Chinese government may merge together several agencies – including the China FDA (CFDA) – into an umbrella State Drug Administration (SDA) with national scope.
HONG KONG – Looking to improve regulatory coordination and supervision of drug and food markets, the Chinese government may merge together several agencies – including the China FDA (CFDA) – into an umbrella State Drug Administration (SDA) with national scope.
HONG KONG – An 11-year-old Chinese biopharma company has recently entered the public's eye with a $10 million series A funding and a clinical trial approval by the CFDA for its biosimilar etanercept.
HONG KONG – An 11-year-old Chinese biopharma company has recently entered the public's eye with a $10 million series A funding and a clinical trial approval by the CFDA for its biosimilar etanercept.
HONG KONG – Taiwan Liposome Co. Ltd. (TLC) has established a joint venture (JV) with China's Jixi Biotechnology Partners dedicated to clinical trials, registration and commercialization of its products in mainland China.
HONG KONG – Less than two months after picking up a big win with the FDA approval for Mylan NV-partnered Herceptin biosimilar Ogivri (trastuzumab-dkst), India's Biocon Ltd. inked a deal with another leader in biosimilar development, Sandoz Inc., a division of Novartis AG, to develop, manufacture and commercialize multiple products in the areas of immunology and oncology.
HONG KONG – Taiwan Liposome Co. Ltd. (TLC) has established a joint venture (JV) with China's Jixi Biotechnology Partners dedicated to clinical trials, registration and commercialization of its products in mainland China.
HONG KONG – Osaka, Japan-based Ono Pharmaceutical Co. Ltd. entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor.
